Weghuber D, Barrett T, Barrientos-Prez M, Gies I, Hesse D, Jeppesen OK, et al
Some patients explore dual-compound options like GLP-Squared Injection, which combines semaglutide with tirzepatide for enhanced results in cases where a single agent plateaus
Clinical data shows tirzepatide produces slightly greater weight loss (22% average reduction) compared to semaglutide (15%), though individual responses vary based on metabolism and genetic predisposition
Cheesecakes (baked & no-bake)
For these reasons, comparing rates of hypoglycemia in clinical trials for NOVOLOG with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that will occur in clinical practice